GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies for serious neurodevelopmental disorders, today announced that it has dosed the first patient in its global ...
These leadership decisions reflect a deliberate evolution of Praxis as we enter a phase driven by commercial launch planning and execution readiness, late-stage development, and strategic corporate ...
Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...
To request an in-person meeting with Gain management on Wednesday during the week of the J.P. Morgan Healthcare Conference, either register at LifeSci Partners Corporate Access Event 2026 or contact ...
The U.S. Food and Drug Administration (FDA) will meet Cognition during a Type C meeting scheduled for the second half of January 2026. During the meeting, the next clinical studies for zervimesine in ...
In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years 1 ...
AUSTIN, Texas — Phase II of the Texas Capitol Complex project is nearing completion, according to JE Dunn Construction, which is facilitating the project alongside the Texas Facilities Commission (TFC ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The buildings in Phase II will ...